TrialBreast cancer research and treatment2017

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.

Hope S Rugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.